Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 11/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391611 | 0.90 | MARS2 (0.61) | MARS2LMNARAB9ACDC7MEN1 | |
| SCHEMBL23419518 | 0.85 | MARS2 (0.45) | MARS2LMNARAB9AMEN1KMT2A | |
| SCHEMBL20595961 | 0.83 | MARS2 (0.63) | MARS2LMNACDC7 | |
| SCHEMBL20595876 | 0.83 | MARS2 (0.61) | MARS2LMNARAB9ACDC7HTT | |
| SCHEMBL20596006 | 0.79 | MARS2 (0.62) | MARS2CDC7KMT2ASMN1; SMN2 | |
| SCHEMBL23391451 | 0.77 | MARS2 (0.81) | MARS2CDC7SMN1; SMN2 | |
| SCHEMBL20596217 | 0.77 | MARS2 (1.00) | MARS2CDC7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20596145 | 0.77 | MARS2 (0.44) | MARS2LMNARAB9AMEN1KMT2A | |
| SCHEMBL20595857 | 0.76 | MARS2 (0.77) | MARS2CDC7MEN1KMT2AHTT | |
| SCHEMBL20596320 | 0.76 | MARS2 (0.77) | MARS2LMNAMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885LMNA 3342/4885RAB9A 2829/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885LMNA 2770/4885RAB9A 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.